https://gabi-journal-net.server1.ech.be/news 2025-07-24T10:39:48+00:00 https://gabi-journal-net.server1.ech.be/news/ema-a-step-closer-to-implementing-new-pharmacovigilance-rules 2012-02-14T15:03:52+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/99-AA010633.jpg https://gabi-journal-net.server1.ech.be/news/registration-of-biosimilars-in-europe-and-the-us 2012-02-14T15:11:50+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/97-AA008586.jpg https://gabi-journal-net.server1.ech.be/news/volume-and-sales-of-drugs-on-the-shortages-list-in-the-us 2012-02-21T13:48:27+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/98-AA010185.jpg https://gabi-journal-net.server1.ech.be/news/commission-urges-greece-to-make-parallel-trade-fair 2012-02-28T08:47:06+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/15-AA010699.jpg https://gabi-journal-net.server1.ech.be/news/prescribing-of-generic-ppis-and-statins-in-scotland 2012-02-28T08:51:26+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/16-AA010705.jpg https://gabi-journal-net.server1.ech.be/news/obama-healthcare-budget-cuts 2012-02-28T08:53:52+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/17-AA010741.jpg https://gabi-journal-net.server1.ech.be/news/greece-drug-shortages 2012-03-15T10:18:16+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/21-AA010935.jpg https://gabi-journal-net.server1.ech.be/news/gabi-launches-gabi-journal 2012-03-16T14:39:25+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/HD_GaBI_Journal_Cover-11.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-interchangeability-increased-costs-and-burden-for-fda 2012-03-20T07:55:34+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/25-AA011049.jpg https://gabi-journal-net.server1.ech.be/news/generics-saved-germany-more-than-25-in-2011 2012-03-23T08:01:20+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/32-AA011143.jpg https://gabi-journal-net.server1.ech.be/news/savings-to-be-made-from-generics-use-in-australia 2012-04-10T09:54:37+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/29-MD002351.jpg https://gabi-journal-net.server1.ech.be/news/south-korean-guidelines-for-biosimilars 2012-04-11T07:27:50+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/34-AA010660.jpg https://gabi-journal-net.server1.ech.be/news/data-publication-may-address-generic-misperceptions 2012-04-13T09:27:35+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/35-AA010652.jpg https://gabi-journal-net.server1.ech.be/news/indian-government-issues-first-compulsory-licence 2012-04-16T12:31:10+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/36-AA010641.jpg https://gabi-journal-net.server1.ech.be/news/aarp-report-highlights-importance-of-generics 2012-04-18T07:01:20+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/40-AA008997.jpg https://gabi-journal-net.server1.ech.be/news/generics-reach-80-and-play-a-critical-role-in-reducing-costs 2012-04-19T09:10:47+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/39-AA008998.jpg https://gabi-journal-net.server1.ech.be/news/canadas-generics-and-brand-name-pharma-come-together-to-tackle-drug-shortages 2012-04-20T07:18:14+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/42-AA008576.jpg https://gabi-journal-net.server1.ech.be/news/brand-name-atorvastatin-cheaper-than-generics 2012-04-23T07:12:07+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/47-MD001813.jpg https://gabi-journal-net.server1.ech.be/news/pricing-of-biosimilars 2012-04-25T06:50:03+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/49-MD002204.jpg https://gabi-journal-net.server1.ech.be/news/fda-announces-public-hearing-on-biosimilars-guidelines 2012-04-27T07:09:42+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/50-MD002352.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-will-not-be-able-to-use-anda-pathway-to-approval 2012-04-30T07:17:50+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/53-MD002445.jpg https://gabi-journal-net.server1.ech.be/news/reimbursement-of-biosimilars 2012-05-02T07:27:40+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/54-AA007289.jpg https://gabi-journal-net.server1.ech.be/news/ema-released-pharmacovigilance-guidelines-for-public-consultation 2012-05-03T07:49:10+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/55-AA010932.jpg https://gabi-journal-net.server1.ech.be/news/attitudes-towards-prescribing-generics-in-malaysia 2012-05-04T07:13:46+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/56-AA011042.jpg https://gabi-journal-net.server1.ech.be/news/canada-drug-shortages 2012-05-07T09:15:16+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/57-AA011104.jpg https://gabi-journal-net.server1.ech.be/news/oncologists-urged-to-embrace-biosimilars-to-help-control-spiralling-costs-of-cancer-care 2012-05-07T09:42:53+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/18-AA010920.jpg https://gabi-journal-net.server1.ech.be/news/patients-do-not-talk-about-generics-with-doctors 2012-05-11T07:33:14+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/63-MD002127.jpg https://gabi-journal-net.server1.ech.be/news/top-10-most-read-gabi-online-articles-in-2011 2012-05-14T07:53:18+00:00 https://gabi-journal-net.server1.ech.be/news/current-and-future-issues-surrounding-biosimilars 2012-05-16T06:55:44+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/62-MD001919.jpg https://gabi-journal-net.server1.ech.be/news/bill-introduced-to-ensure-generics-get-180-day-exclusivity 2012-05-18T08:03:07+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/61-MD001866.jpg https://gabi-journal-net.server1.ech.be/news/fda-approves-generic-versions-of-blood-thinner-clopidogrel 2012-05-23T08:51:36+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/70-MD002162.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-dilemma-over-reference-products 2012-06-06T08:37:01+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/68-MD002148.jpg https://gabi-journal-net.server1.ech.be/news/ema-publishes-procedural-advice-for-biosimilars 2012-06-06T08:37:19+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/74-MD002193.jpg https://gabi-journal-net.server1.ech.be/news/removal-of-barriers-for-the-global-development-of-biosimilars 2012-06-08T07:23:11+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/72-MD002170.jpg https://gabi-journal-net.server1.ech.be/news/ema-reviews-its-first-biosimilar-monoclonal-antibody 2012-06-13T07:13:59+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/78-MD002368.jpg https://gabi-journal-net.server1.ech.be/news/comparison-of-brand-name-and-biosimilar-etanercept-in-korea 2012-06-18T07:35:36+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/85-MD002443.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-marketed-in-europe 2012-06-22T08:23:16+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/99-AA010633.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-approved-and-marketed-in-belgium 2012-06-25T07:17:45+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/95-AA008568.jpg https://gabi-journal-net.server1.ech.be/news/fdas-public-hearing-on-biosimilars-draft-guidances 2012-06-27T07:00:58+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/08-AA007288.jpg https://gabi-journal-net.server1.ech.be/news/immunogenicity-of-biologicals 2012-06-29T06:59:44+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/06-AA011105.jpg https://gabi-journal-net.server1.ech.be/news/mylan-moving-ahead 2012-07-02T07:15:28+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/102-MD001880.jpg https://gabi-journal-net.server1.ech.be/news/samsung-to-launch-biosimilars-by-2015-at-half-current-prices 2012-07-02T15:28:31+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/69-MD002136.jpg https://gabi-journal-net.server1.ech.be/news/ema-finalises-biosimilar-monoclonal-antibody-guidelines 2012-07-04T07:29:06+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/114-MD002317.jpg https://gabi-journal-net.server1.ech.be/news/ema-finalises-biosimilar-monoclonal-antibody-guidelines-2 2012-07-06T08:46:22+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/110-MD002391.jpg https://gabi-journal-net.server1.ech.be/news/amgen-welcomes-biosimilar-monoclonal-antibody-guideline 2012-08-09T09:33:18+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/113-MD002138.jpg https://gabi-journal-net.server1.ech.be/news/prescriber-caution-is-likely-over-biosimilars 2012-08-13T07:00:40+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/15-AA010699.jpg https://gabi-journal-net.server1.ech.be/news/brazilian-guidelines-for-biosimilars 2012-08-15T07:00:52+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/16-AA010705.jpg https://gabi-journal-net.server1.ech.be/news/merck-kgaa-and-dr-reddys-to-collaborate-on-biosimilar-mabs 2012-08-17T08:36:16+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/20-AA010933.jpg https://gabi-journal-net.server1.ech.be/news/attitudes-and-beliefs-are-powerful-influences-on-generics-use 2012-08-20T09:21:22+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/21-AA010935.jpg https://gabi-journal-net.server1.ech.be/news/ema-revised-guideline-on-quality-of-biosimilar-medicines-open-for-comments 2012-08-22T08:30:21+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/19-AA010921.jpg https://gabi-journal-net.server1.ech.be/news/who-guidelines-on-biosimilars-case-studies-and-discussion-highlights 2012-08-27T12:18:45+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/107-MD0022051.jpg https://gabi-journal-net.server1.ech.be/news/eu-guidelines-for-biosimilars 2012-08-29T08:30:27+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/20-AA010933.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-policies-in-italy 2012-08-31T08:30:57+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/103-MD001949.jpg https://gabi-journal-net.server1.ech.be/news/guidelines-for-substitution-of-generics-in-the-netherlands 2012-09-03T08:30:19+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/105-MD002135.jpg https://gabi-journal-net.server1.ech.be/news/india-releases-draft-similar-biologic-guidelines 2012-09-17T08:30:40+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/121-AA008574.jpg https://gabi-journal-net.server1.ech.be/news/ema-finalises-pharmacovigilance-guidance 2012-09-19T08:30:29+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/129-AA010946.jpg https://gabi-journal-net.server1.ech.be/news/mexican-guidelines-for-biocomparables 2012-09-26T08:30:07+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/96-AA008591.jpg https://gabi-journal-net.server1.ech.be/news/us-supreme-court-ruling-means-biosimilars-pathway-safe 2012-09-28T08:30:12+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/130-AA008570.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-infliximab-equivalence-proven-in-phase-iii-trial 2012-10-01T08:30:13+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/127-AA010925.jpg https://gabi-journal-net.server1.ech.be/news/deal-struck-over-development-of-herceptin-biosimilar 2012-10-05T08:30:51+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/136-AA011035.jpg https://gabi-journal-net.server1.ech.be/news/australia-moves-towards-pricing-policy-for-biosimilars 2012-10-08T08:30:19+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/137-AA010941.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-monoclonal-antibody-approved-in-korea 2012-10-10T07:33:59+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/132-AA011051.jpg https://gabi-journal-net.server1.ech.be/news/testing-for-unwanted-immunogenicity-from-biologicals 2012-10-12T08:30:28+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/145-AA010351.jpg https://gabi-journal-net.server1.ech.be/news/asian-companies-venture-into-biosimilars-for-kidney-failure 2012-10-15T08:30:56+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/141-AA010176.jpg https://gabi-journal-net.server1.ech.be/news/malaysia-objects-to-patent-terms-in-free-trade-agreement 2012-10-19T08:30:00+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/02-AA010638.jpg https://gabi-journal-net.server1.ech.be/news/growing-economies-growing-markets-a-bright-future-for-biosimilars 2012-11-05T09:30:42+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/19-AA010921.jpg https://gabi-journal-net.server1.ech.be/news/coupons-help-big-pharma-to-fend-off-generics 2012-11-08T09:30:35+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/14-AA010696.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-comparability-debate-continues 2012-11-13T10:50:57+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/32-AA011143.jpg https://gabi-journal-net.server1.ech.be/news/maximising-the-potential-of-generics-in-abu-dhabi 2012-11-13T12:14:03+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/29-MD002351.jpg https://gabi-journal-net.server1.ech.be/news/poor-quality-pharma-ingredients-abound-in-china 2012-11-19T09:30:51+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/24-AA011041.jpg https://gabi-journal-net.server1.ech.be/news/italian-medicines-agency-publishes-concept-paper-on-biosimilars 2012-11-21T09:30:10+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/43-AA007237.jpg https://gabi-journal-net.server1.ech.be/news/abpi-concerned-about-medicines-misconceptions 2012-11-23T09:30:47+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/40-AA008997.jpg https://gabi-journal-net.server1.ech.be/news/generics-substitution-irelands-plan-for-reference-pricing 2012-11-26T09:02:39+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/39-AA008998.jpg https://gabi-journal-net.server1.ech.be/news/ema-to-accept-biosimilar-reference-medicines-from-outside-eea 2012-11-27T09:30:31+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/53-MD002445.jpg https://gabi-journal-net.server1.ech.be/news/ema-publishes-revised-biosimilar-qa-document-for-patients 2012-11-28T09:30:02+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/52-MD002433.jpg https://gabi-journal-net.server1.ech.be/news/overview-of-research-on-safety-and-immunogenicity-of-biosimilars-in-2012 2012-11-29T09:30:07+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/51-MD002353.jpg https://gabi-journal-net.server1.ech.be/news/australian-patients-very-positive-about-generics 2012-11-30T09:30:23+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/49-MD002204.jpg https://gabi-journal-net.server1.ech.be/news/suggestions-for-increasing-generics-use-in-abu-dhabi 2012-12-03T09:30:40+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/45-AA005795.jpg https://gabi-journal-net.server1.ech.be/news/the-common-european-submission-platform 2012-12-05T08:12:17+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/63-MD002127.jpg https://gabi-journal-net.server1.ech.be/news/overview-of-research-on-biosimilaritycomparability-and-interchangeability-of-biosimilars-2012 2012-12-07T09:30:26+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/62-MD001919.jpg https://gabi-journal-net.server1.ech.be/news/india-plans-further-cuts-to-drug-prices 2012-12-12T09:30:07+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/59-MD002189.jpg https://gabi-journal-net.server1.ech.be/news/generic-medicine-switches-confuse-patients-and-reduce-adherence 2012-12-18T09:35:48+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/67-MD002147.jpg https://gabi-journal-net.server1.ech.be/news/generic-drug-user-fees-come-into-effect 2012-12-20T09:31:48+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/64-MD002129.jpg https://gabi-journal-net.server1.ech.be/news/msf-launches-online-patent-opposition-database 2012-12-27T09:36:52+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/78-MD002368.jpg https://gabi-journal-net.server1.ech.be/news/ema-approves-first-generic-imatinib 2013-01-08T11:50:47+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/80-MD002386.jpg https://gabi-journal-net.server1.ech.be/news/the-latest-biosimilars-agreements 2013-01-11T09:35:12+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/77-MD002338.jpg https://gabi-journal-net.server1.ech.be/news/german-court-rules-seroquel-xr-patent-invalid 2013-01-18T09:30:31+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/83-MD002439.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-policies-in-spain 2013-01-21T09:30:24+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Spain-Sub-Page-Image.jpg https://gabi-journal-net.server1.ech.be/news/pharmaceutical-trade-barriers-are-falling 2013-01-23T09:30:16+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GW-1185I-image.jpg https://gabi-journal-net.server1.ech.be/news/abpi-issues-position-paper-on-biosimilars 2013-01-25T09:30:42+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/82-MD002431.jpg https://gabi-journal-net.server1.ech.be/news/major-shake-up-of-api-import-rules-in-europe 2013-01-28T09:30:14+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GW-1189I-image.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-approved-and-marketed-in-germany 2013-01-30T09:30:52+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/86-MD002444.jpg https://gabi-journal-net.server1.ech.be/news/overview-of-research-on-general-policies-aimed-at-generics-in-2012 2013-02-01T09:31:18+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/98-AA010185.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-policies-in-the-uk 2013-02-04T09:31:04+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/UK-Sub-Page-Image.jpg https://gabi-journal-net.server1.ech.be/news/ema-risk-management-plans-may-increase-prescriber-confidence-in-biosimilars 2013-02-05T12:48:19+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/100-AA010656.jpg https://gabi-journal-net.server1.ech.be/news/marvel-withdraws-biosimilar-insulin-applications 2013-02-08T09:31:05+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/104-MD001918.jpg https://gabi-journal-net.server1.ech.be/news/history-of-biosimilar-monoclonal-antibodies-regulation-in-eu 2013-02-11T08:36:00+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/121-AA008574.jpg https://gabi-journal-net.server1.ech.be/news/generic-drug-prices-decrease-brand-name-prices-increase 2013-02-13T09:30:08+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/108-MD002320.jpg https://gabi-journal-net.server1.ech.be/news/teva-cost-cutting-and-re-organization 2013-02-15T09:30:59+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/118-MD002467.jpg https://gabi-journal-net.server1.ech.be/news/overview-of-research-on-manufacturing-statistics-and-innovations-of-biosimilars-in-2012 2013-02-18T09:30:16+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/116-MD002198.jpg https://gabi-journal-net.server1.ech.be/news/overview-of-research-on-specific-policies-aimed-at-generics-in-2012 2013-02-20T09:30:15+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/114-MD002317.jpg https://gabi-journal-net.server1.ech.be/news/comparison-of-epars-for-g-csf-biosimilars-approved-in-europe 2013-02-22T09:30:50+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/113-MD002138.jpg https://gabi-journal-net.server1.ech.be/news/originator-biologicals-approved-and-marketed-in-germany 2013-02-27T09:30:52+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/111-ST001975.jpg https://gabi-journal-net.server1.ech.be/news/ema-publishes-draft-guideline-for-biosimilar-human-insulin 2013-03-04T15:16:59+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/128-AA010937.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-monoclonal-antibodies-on-the-horizon-in-europe 2013-03-04T15:21:56+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/127-AA010925.jpg https://gabi-journal-net.server1.ech.be/news/significance-of-locally-produced-biosimilars-in-iran 2013-03-07T08:19:39+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/126-AA010686.jpg https://gabi-journal-net.server1.ech.be/news/french-government-pushing-generics 2013-03-08T09:30:54+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/125-MD002341.jpg https://gabi-journal-net.server1.ech.be/news/brand-name-and-generics-labels-dont-match 2013-03-15T09:30:14+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/137-AA010941.jpg https://gabi-journal-net.server1.ech.be/news/overview-of-research-on-analytical-techniques-in-the-manufacturing-of-biosimilars-in-2012 2013-03-18T09:30:02+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/136-AA011035.jpg https://gabi-journal-net.server1.ech.be/news/brand-name-drugmaker-can-be-sued-for-harm-caused-by-generic-drug 2013-03-20T09:30:48+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/132-AA011051.jpg https://gabi-journal-net.server1.ech.be/news/biosimilarity-and-interchangeability-under-the-bpci-act 2013-03-22T09:30:32+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/146-AA011058.jpg https://gabi-journal-net.server1.ech.be/news/pay-for-delay-on-the-increase-in-the-us 2013-03-25T09:30:03+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/145-AA010351.jpg https://gabi-journal-net.server1.ech.be/news/top-10-most-read-gabi-online-articles-in-2012 2013-03-27T09:30:08+00:00 https://gabi-journal-net.server1.ech.be/news/india-issues-more-compulsory-licences 2013-03-29T09:30:58+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/144-AA011061.jpg https://gabi-journal-net.server1.ech.be/news/generic-antiepileptic-drugs-bioequivalent-to-brand-name-drugs 2013-04-01T08:30:37+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/142-AA010936.jpg https://gabi-journal-net.server1.ech.be/news/positive-phase-i-data-for-infliximab-biosimilar 2013-04-03T08:30:40+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/143-AA010952.jpg https://gabi-journal-net.server1.ech.be/news/overview-of-research-on-regulatory-issues-for-generics-in-2012 2013-04-05T08:30:27+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/140-AA008592.jpg https://gabi-journal-net.server1.ech.be/news/mobilization-of-stem-cells-in-healthy-donors-by-g-csf-biosimilars-shows-comparable-efficacy-and-safety-to-neupogen 2013-04-08T08:30:14+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/02-AA010638.jpg https://gabi-journal-net.server1.ech.be/news/hiv-generics-could-significantly-cut-treatment-costs 2013-04-12T08:30:05+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/01-AA007239.jpg https://gabi-journal-net.server1.ech.be/news/overview-of-research-on-g-csf-biosimilars-in-2012 2013-04-15T08:30:27+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/03-AA010722.jpg https://gabi-journal-net.server1.ech.be/news/fda-gives-details-of-generic-drug-user-fees 2013-04-17T08:30:36+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/149-AA010954.jpg https://gabi-journal-net.server1.ech.be/news/draft-revision-of-biosimilar-low-molecular-weight-heparin-guideline 2013-04-22T08:30:46+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/08-AA007288.jpg https://gabi-journal-net.server1.ech.be/news/biotech-firms-try-to-limit-biosimilar-substitution-in-us 2013-04-24T08:30:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/12-AA010179.jpg https://gabi-journal-net.server1.ech.be/news/assessment-of-biosimilarity-under-the-bpci-act 2013-04-29T08:30:54+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/07-AA011110.jpg https://gabi-journal-net.server1.ech.be/news/prescribing-in-scotland-increases-but-drug-costs-drop 2013-05-03T08:30:07+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/11-AA010165.jpg https://gabi-journal-net.server1.ech.be/news/g-csf-biosimilars-world-marrow-donor-association-position 2013-05-06T08:30:47+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/06-AA011105.jpg https://gabi-journal-net.server1.ech.be/news/medicines-spending-in-brazil 2013-05-08T08:30:34+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/27-MD002442.jpg https://gabi-journal-net.server1.ech.be/news/generics-policies-in-europe-have-room-for-improvement 2013-05-10T08:30:49+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/16-AA010705.jpg https://gabi-journal-net.server1.ech.be/news/inequality-in-europe-over-access-to-biologicals-for-arthritis 2013-05-13T08:30:02+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/24-AA011041.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-to-replace-70-of-chemical-drugs 2013-05-15T08:30:16+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/23-AA011020.jpg https://gabi-journal-net.server1.ech.be/news/meps-adopt-directive-to-give-quicker-access-to-generics 2013-05-17T08:30:11+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/14-AA010696.jpg https://gabi-journal-net.server1.ech.be/news/biologicals-in-eu-to-be-identified-by-brand-names 2013-05-20T08:30:48+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/18-AA010920.jpg https://gabi-journal-net.server1.ech.be/news/assessment-of-interchangeability-under-the-bpci-act 2013-05-22T08:30:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/20-AA010933.jpg https://gabi-journal-net.server1.ech.be/news/the-ethics-of-biosimilars 2013-05-27T08:30:57+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Ethics-V13C05.jpg https://gabi-journal-net.server1.ech.be/news/merck-makes-biosimilars-deal-with-samsung-bioepis 2013-05-29T08:30:25+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/19-AA010921.jpg https://gabi-journal-net.server1.ech.be/news/india-supplies-20-of-generic-drugs-worldwide 2013-06-05T08:30:36+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/India-V13C03.jpg https://gabi-journal-net.server1.ech.be/news/ms-patient-dies-from-immunogenicity-to-biological-drug 2013-06-07T08:30:17+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/MS-Nerve-cells-V13C03.jpg https://gabi-journal-net.server1.ech.be/news/egypt-issues-draft-guidelines-for-biosimilars 2013-06-10T08:30:48+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Egypt-EDA-V13C04.jpg https://gabi-journal-net.server1.ech.be/news/drugmakers-accused-of-stopping-shipments-to-greece 2013-06-17T08:30:37+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/29-MD002351.jpg https://gabi-journal-net.server1.ech.be/news/japan-approves-second-biosimilar-g-csf 2013-06-19T08:30:48+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/G-CSF-V13C08.png https://gabi-journal-net.server1.ech.be/news/ema-releases-guidelines-on-biosimilar-interferon-beta-and-r-fsh 2013-06-21T08:30:59+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/DNA-Kaku-V13C15.jpg https://gabi-journal-net.server1.ech.be/news/use-of-venlafaxine-in-austria-after-introduction-of-generics 2013-06-24T08:30:44+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Venlafaxine-V13C15.png https://gabi-journal-net.server1.ech.be/news/biosimilars-bills-move-on-in-two-us-states 2013-06-26T08:30:48+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/US-map-CO+FL-V13C15.png https://gabi-journal-net.server1.ech.be/news/greece-says-no-to-automatic-substitution-of-biologicals 2013-06-28T08:30:21+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Greece-flag-V13C15.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-filgrastim-provides-cost-savings-for-treating-febrile-neutropenia 2013-06-20T12:25:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/91-AA007225.jpg https://gabi-journal-net.server1.ech.be/news/how-are-biosimilars-special 2013-07-03T08:30:27+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Clinician1-MD002408-V13C22.jpg https://gabi-journal-net.server1.ech.be/news/eu-api-law-causing-concern-among-api-producers 2013-07-05T08:30:26+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/API-V13C22.jpg https://gabi-journal-net.server1.ech.be/news/changes-in-risperidone-use-in-austria-after-introduction-of-generics 2013-07-08T08:30:06+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Risperidone-3D-balls-V13C22.png https://gabi-journal-net.server1.ech.be/news/evergreening-patents-may-make-drugs-too-costly-for-patients-in-thailand 2013-07-10T08:30:58+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Evergreen-MSF-V13C22.jpg https://gabi-journal-net.server1.ech.be/news/when-will-the-us-biosimilars-pathway-be-used 2013-07-12T08:30:28+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/FDA-logo-V13C22.jpg https://gabi-journal-net.server1.ech.be/news/colombia-issues-draft-decree-for-registration-of-biosimilars 2013-07-15T08:30:19+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Colombia-Flag-V13C22.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-in-rheumatology 2013-07-17T08:30:05+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Rheumatology-RCPI-V13C29.jpg https://gabi-journal-net.server1.ech.be/news/us-state-biosimilar-substitution-bill-becomes-law 2013-07-19T08:30:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Law-V13C29.jpg https://gabi-journal-net.server1.ech.be/news/why-choose-generic-medicines-initiative-launched-in-australia 2013-07-22T08:30:46+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Australia-flag-V13C29.jpg https://gabi-journal-net.server1.ech.be/news/use-of-generic-medicines-in-ireland 2013-07-24T08:30:40+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Ireland-flag-V13C29.jpg https://gabi-journal-net.server1.ech.be/news/generics-drugmakers-should-be-held-responsible-for-injuries 2013-07-26T08:30:24+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Generic-V13C05.jpg https://gabi-journal-net.server1.ech.be/news/saving-money-in-the-european-healthcare-system-with-biosimilars 2013-07-02T12:44:44+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/76-MD002337.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-g-csf-prescribed-more-than-originator 2013-08-06T11:13:41+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/G-CSF-V13C08.png https://gabi-journal-net.server1.ech.be/news/us-ftc-sides-with-generics-makers-over-drug-samples 2013-08-07T08:30:35+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Pills-V13D05.jpg https://gabi-journal-net.server1.ech.be/news/huge-differences-in-prescription-drug-prices-in-ireland 2013-08-09T08:30:10+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Ireland-flag-V13C29.jpg https://gabi-journal-net.server1.ech.be/news/research-on-biosimilars-in-anaemia-and-diabetes 2013-08-12T08:30:17+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Research-V13D05.jpg https://gabi-journal-net.server1.ech.be/news/amgens-biosimilar-plans 2013-08-16T08:30:34+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Biologicals-1-V13D05.jpg https://gabi-journal-net.server1.ech.be/news/quality-similarity-and-safety-of-biosimilars 2013-08-19T08:30:01+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Quality-similarity-and-safety-V13D12.jpg https://gabi-journal-net.server1.ech.be/news/cost-savings-from-use-of-generic-medicines-in-ireland 2013-08-21T08:30:40+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Health-on-a-Budget-V13D12.jpg https://gabi-journal-net.server1.ech.be/news/efficacy-extrapolation-and-interchangeability-of-biosimilars 2013-08-23T08:30:07+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Efficacy-Extrapolation-Interchangeability-V13D19.jpg https://gabi-journal-net.server1.ech.be/news/patients-in-us-turn-to-generics-to-save-money 2013-08-26T08:30:56+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Patient-MD002316-V13C05.jpg https://gabi-journal-net.server1.ech.be/news/quality-of-generics-in-south-africa 2013-08-30T08:30:40+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Generic-V13C05.jpg https://gabi-journal-net.server1.ech.be/news/more-uk-patients-affected-by-drug-shortages-in-2012 2013-09-02T08:30:31+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Drug-shortages-V13C22.png https://gabi-journal-net.server1.ech.be/news/eu-publishes-consensus-report-on-biosimilars 2013-09-06T08:30:08+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Consensus-Report-V13E03.png https://gabi-journal-net.server1.ech.be/news/innovation-in-the-generics-industry 2013-09-09T10:36:39+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Innovation-V13E10.jpg https://gabi-journal-net.server1.ech.be/news/the-biggest-drug-patent-losses-for-2013 2013-09-11T08:30:22+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Patent-1-V13E17.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-and-us-exclusivity 2013-09-13T08:30:13+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/DNA-Kaku-V13C15.jpg https://gabi-journal-net.server1.ech.be/news/kazakhstan-russia-ukraine-to-change-drug-reimbursement-schemes 2013-09-16T08:30:15+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/CIS-emblem-V13E24.jpg https://gabi-journal-net.server1.ech.be/news/use-of-g-csf-biosimilars-for-stem-cell-mobilization-in-healthy-donors 2013-09-18T08:30:06+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Stem-Cell-V13E24.jpg https://gabi-journal-net.server1.ech.be/news/equivalence-of-generic-immunosuppressants 2013-09-20T08:30:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Transplant1-AA010155-V13E31.jpg https://gabi-journal-net.server1.ech.be/news/biopharmaceutical-products-in-iran 2013-09-23T08:30:56+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Iran-flag-V13E31.jpg https://gabi-journal-net.server1.ech.be/news/positive-post-marketing-data-for-biosimilar-epoetin 2013-09-25T08:30:51+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Erythropoietin-V13F07.png https://gabi-journal-net.server1.ech.be/news/use-of-g-csf-biosimilars-for-stem-cell-mobilization-in-autologous-transplantation 2013-09-27T08:30:19+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Autologous-Stem-Cell-Transplant-V13F07.jpg https://gabi-journal-net.server1.ech.be/news/biologicals-sales-have-almost-doubled-since-2006 2013-09-30T08:30:10+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/74-MD002193.jpg https://gabi-journal-net.server1.ech.be/news/use-of-g-csf-biosimilars-for-reduction-of-fever 2013-10-02T08:30:20+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Autologous-Stem-Cell-Transplant-V13F07.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-monoclonal-antibodies-and-pharmacovigilance-in-europe 2013-10-09T08:30:11+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Pharmacovigilance-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/enhancing-prescribing-efficiency-in-the-republic-of-srpska 2013-10-11T08:30:58+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Srpska-flag-V13F28.jpg https://gabi-journal-net.server1.ech.be/news/infliximab-biosimilar-comparable-to-remicade 2013-10-16T08:30:49+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Remicade-V13F28.jpg https://gabi-journal-net.server1.ech.be/news/erythropoietin-biosimilars-in-bone-marrow-transplantation-and-stem-cell-donation 2013-10-18T08:30:24+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Erythropoietin-V13F07.png https://gabi-journal-net.server1.ech.be/news/ema-approves-first-monoclonal-antibody-biosimilars 2013-10-23T08:30:56+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Approved-V13G05.jpg https://gabi-journal-net.server1.ech.be/news/generics-combo-non-inferior-to-treatment-with-enbrel 2013-10-25T08:30:49+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Rheumatology-RCPI-V13C29.jpg https://gabi-journal-net.server1.ech.be/news/patient-care-threatened-by-cancer-drug-shortages 2013-10-28T09:30:24+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Drug-shortages-V13C22.png https://gabi-journal-net.server1.ech.be/news/regulation-of-similar-biotherapeutic-products-in-latin-america 2013-11-06T09:30:41+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/02-AA010638.jpg https://gabi-journal-net.server1.ech.be/news/california-governor-vetoes-biosimilars-bill 2013-11-08T09:30:54+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/US-map-CA-V13J18.jpg https://gabi-journal-net.server1.ech.be/news/the-future-of-nanomedicines-nanosimilars 2013-11-12T09:30:28+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Nanoparticle-V13J18.jpg https://gabi-journal-net.server1.ech.be/news/eu-guidelines-for-nanosimilars 2013-11-19T09:30:14+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/EMA-logo-2-V13F14.jpg https://gabi-journal-net.server1.ech.be/news/canada-clarifies-regulatory-pathway-for-subsequent-entry-low-molecular-weight-heparins 2013-11-21T09:30:22+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Health-Canada-V13I20.jpg https://gabi-journal-net.server1.ech.be/news/naming-requirements-in-australian-biosimilars-guidance 2013-11-26T09:30:07+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Naming-3-V13J04.jpg https://gabi-journal-net.server1.ech.be/news/celltrion-applies-for-biosimilar-infliximab-approval-in-japan 2013-12-03T09:30:33+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Infliximab-V13I13.jpg https://gabi-journal-net.server1.ech.be/news/authorized-generics-reduce-drug-prices 2013-12-05T09:30:36+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/ANDA-Approval-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/india-to-make-prescribing-of-generics-compulsory 2013-12-10T09:30:44+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Generic-V13C05.jpg https://gabi-journal-net.server1.ech.be/news/australia-issues-new-biosimilars-guidance 2013-12-12T09:30:19+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/TGA-Logo-V13H23.gif https://gabi-journal-net.server1.ech.be/news/interchangeability-of-gabapentin-generic-formulations-in-the-netherlands-summary-of-a-comparative-bioavailability-study 2013-12-17T09:30:29+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Gabapentin-V13H23.png https://gabi-journal-net.server1.ech.be/news/how-to-avoid-drug-shortages 2013-12-26T09:30:54+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Drug-shortages-V13C22.png https://gabi-journal-net.server1.ech.be/news/implications-of-the-changes-in-venlafaxine-utilization-in-sweden-following-generics 2014-01-02T09:30:15+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/118-MD002467.jpg https://gabi-journal-net.server1.ech.be/news/south-africa-introduces-new-patent-policy 2014-01-09T09:30:57+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Patent-1-V13E17.jpg https://gabi-journal-net.server1.ech.be/news/uk-biosimilars-uptake-lower-than-in-some-other-eu-countries 2014-01-21T09:30:37+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/UK-flag-V13I20.jpg https://gabi-journal-net.server1.ech.be/news/use-of-generic-anti-asthmatic-drugs-in-morocco 2014-01-23T09:30:12+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/85-MD002443.jpg https://gabi-journal-net.server1.ech.be/news/health-canada-announces-plans-to-tackle-drug-shortages 2014-01-28T09:30:42+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Health-Canada-V13I20.jpg https://gabi-journal-net.server1.ech.be/news/more-immunogenicity-data-needed-for-biosimilar-mabs 2014-01-30T09:30:20+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Biologicals-3-V13E17.gif https://gabi-journal-net.server1.ech.be/news/extrapolation-of-biosimilar-infliximab-indications-to-inflammatory-bowel-disease 2014-02-13T09:30:05+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/IBD-2-V13J25.jpg https://gabi-journal-net.server1.ech.be/news/similar-biotherapeutic-products-approved-and-marketed-in-latin-america 2014-02-18T09:30:06+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Latin-America-V13J25.png https://gabi-journal-net.server1.ech.be/news/sandoz-makes-deal-with-shire-for-authorized-adderall-xr-generic 2014-02-20T14:09:52+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Amphetamine-V13L13.png https://gabi-journal-net.server1.ech.be/news/sandoz-gains-danish-approval-for-innovative-asthma-inhaler 2014-03-06T09:30:55+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Inhaler-MD002004-V13J25.jpg https://gabi-journal-net.server1.ech.be/news/ega-commends-ema-workshop-on-biosimilars-guidelines 2014-04-03T08:30:42+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Guidance-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/ema-launches-public-catalogue-of-drug-shortages 2014-04-08T08:30:49+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Drug-Shortages-FDA-V13K15.jpg https://gabi-journal-net.server1.ech.be/news/etanercept-biosimilar-has-comparable-pharmacokinetics-to-enbrel 2014-04-15T08:30:54+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Pharmacokinetics-1-V13K15.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-naming-debate-intensifies 2014-04-17T08:30:59+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Naming-2-V13K22.jpg https://gabi-journal-net.server1.ech.be/news/fda-awards-grant-to-study-generic-transplant-drug-tacrolimus 2014-04-22T08:30:58+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Transplant2-AA010142-V13K22.jpg https://gabi-journal-net.server1.ech.be/news/shortage-of-hivaids-drugs-in-south-africa 2014-05-08T08:30:00+00:00 https://gabi-journal-net.server1.ech.be/news/germany-wants-to-increase-biosimilars-penetration 2014-05-13T08:30:51+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Biologicals-4-V13L13.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-trastuzumab-approved-in-korea 2014-05-20T08:30:48+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Trastuzumab-Herceptin-V13D12.jpg https://gabi-journal-net.server1.ech.be/news/switching-to-generic-cyclosporine-a-after-heart-transplant-safe 2014-05-27T08:30:03+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Transplant2-AA010142-V13K22.jpg https://gabi-journal-net.server1.ech.be/news/effects-of-income-competition-and-procurement-on-drug-prices-in-emerging-markets 2014-05-29T08:30:17+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Pay-for-Delay-DrugsMoneyGeneric-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/challenges-and-opportunities-for-anticancer-mabs 2014-04-07T14:47:52+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Cancer-Cell-V13I20.jpg https://gabi-journal-net.server1.ech.be/news/australia-to-adopt-emas-monoclonal-antibody-guideline 2014-07-14T14:01:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/TGA-Logo-V13H23.gif https://gabi-journal-net.server1.ech.be/news/new-zealand-guidelines-for-biosimilars 2014-09-04T12:41:17+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/nz-mmdsa-logo.gif https://gabi-journal-net.server1.ech.be/news/fda-and-health-canada-streamline-drug-submissions 2014-09-18T12:52:22+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/shaking-hands-v13d29.jpg https://gabi-journal-net.server1.ech.be/news/european-trade-organizations-worried-about-pharmacovigilance-fees 2014-09-30T13:04:54+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Pharmacovigilance-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-approved-in-japan 2014-10-02T13:06:20+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/DNA-Helix-Serendipity-V13K22.jpg https://gabi-journal-net.server1.ech.be/news/generics-contribution-to-availability-of-essential-medicines 2014-10-06T12:00:45+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Pay-for-Delay-DrugsMoneyGeneric-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-approved-in-australia 2014-09-26T06:41:17+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Biologicals-1-V13D05.jpg https://gabi-journal-net.server1.ech.be/news/how-safe-is-zarzio-after-five-years-clinical-experience 2014-10-08T08:30:14+00:00 https://gabi-journal-net.server1.ech.be/news/ema-and-fda-extend-quality-collaboration 2014-10-14T08:37:34+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/teamwork-original.jpg https://gabi-journal-net.server1.ech.be/news/diabetes-and-high-blood-pressure-generics-in-europe 2014-10-24T07:55:48+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/diabetes-cure-v14c20.jpg https://gabi-journal-net.server1.ech.be/news/bill-proposes-extension-of-patents-for-new-uses-of-biologicals 2014-11-13T08:48:44+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Patent-1-V13E17.jpg https://gabi-journal-net.server1.ech.be/news/ema-issues-concept-paper-for-revision-of-immunogenicity-guideline 2014-11-05T08:59:16+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/medical-globe-v13k15.jpg https://gabi-journal-net.server1.ech.be/news/anticompetitive-practices-come-under-scrutiny-in-australia 2014-11-07T09:02:32+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Australia-flag-V13C29.jpg https://gabi-journal-net.server1.ech.be/news/cost-savings-and-use-of-generics-in-europe 2014-11-17T09:03:32+00:00 https://gabi-journal-net.server1.ech.be/news/us-ftc-hopes-to-collect-us1-billion-from-pay-for-delay-settlement 2014-11-19T09:05:41+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Pay-for-Delay-DrugsMoneyGeneric-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/the-generics-market-in-china 2014-11-21T09:07:21+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/china-flag.jpg https://gabi-journal-net.server1.ech.be/news/who-investigates-use-of-a-biological-qualifier-for-biosimilars 2014-11-25T09:09:33+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Naming-2-V13K22.jpg https://gabi-journal-net.server1.ech.be/news/australian-price-cuts-make-pbs-affordable 2014-12-03T09:20:45+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Pay-for-Delay-DrugsMoneyGeneric-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/fda-releases-bioequivalence-guidance-for-26-generics 2014-12-11T09:25:49+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Guidance-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/positive-impact-of-a-value-based-approach-to-health-care 2014-12-15T09:27:20+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/59-MD002189.jpg https://gabi-journal-net.server1.ech.be/news/cost-cutting-in-europe-may-affect-generics-sustainability 2014-12-19T09:31:56+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/52-MD002433.jpg https://gabi-journal-net.server1.ech.be/news/cost-savings-to-be-made-by-switching-to-zarzio 2014-11-11T09:00:09+00:00 https://gabi-journal-net.server1.ech.be/news/phase-i-studies-of-infliximab-and-rituximab-biosimilars-demonstrate-pharmacokinetic-similarity 2015-04-01T09:53:46+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/rituximab-v13d29.png https://gabi-journal-net.server1.ech.be/news/the-generics-market-in-taiwan 2015-01-08T09:53:41+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/taiwan-v14e02.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-for-inflammatory-bowel-disease-in-norway 2015-01-12T09:55:58+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/ibd-4.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-trastuzumab-candidates-in-phase-iii-development 2015-01-14T09:58:05+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Trastuzumab-Herceptin-V13D12.jpg https://gabi-journal-net.server1.ech.be/news/the-brazilian-generics-market 2015-01-16T10:00:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Brazil-flag-V13C03.jpg https://gabi-journal-net.server1.ech.be/news/fda-releases-further-biosimilars-guidance 2015-01-20T10:04:55+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Guidance-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-epoetin-shows-good-safety-profile-in-post-authorization-study 2015-01-22T10:06:45+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/quality-service-and-safety.jpg https://gabi-journal-net.server1.ech.be/news/pharmacists-attitudes-towards-generics-in-czech-republic 2015-01-26T10:09:08+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/70-MD002162.jpg https://gabi-journal-net.server1.ech.be/news/impact-of-delisting-arbs-in-denmark 2015-01-28T10:11:23+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/118-MD002467.jpg https://gabi-journal-net.server1.ech.be/news/ema-changes-transparency-plans-to-increase-access-to-data 2015-03-20T10:47:50+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/135-AA010177.jpg https://gabi-journal-net.server1.ech.be/news/data-protection-provisions-in-ceta 2015-03-30T09:52:04+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/136-AA011035.jpg https://gabi-journal-net.server1.ech.be/news/patients-perception-of-generics-in-the-philippines 2015-02-06T10:21:36+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/109-MD002387.jpg https://gabi-journal-net.server1.ech.be/news/the-global-biologicals-market 2015-02-16T10:25:02+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/globe-aa008897-v13h02.jpg https://gabi-journal-net.server1.ech.be/news/can-the-pursuit-of-biosimilar-interchangeability-go-too-far 2015-03-02T10:38:06+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Quality-similarity-and-safety-V13D12.jpg https://gabi-journal-net.server1.ech.be/news/ema-criticized-for-change-in-data-transparency-plans 2015-03-06T10:41:00+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/data-transparency-wpress-v13c15.jpg https://gabi-journal-net.server1.ech.be/news/factors-influencing-use-of-generic-asthma-drugs-in-morocco 2015-03-10T10:42:53+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/110-MD002391.jpg https://gabi-journal-net.server1.ech.be/news/ecco-position-statement-on-biosimilars 2015-03-12T10:44:09+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/ibd-4.jpg https://gabi-journal-net.server1.ech.be/news/influence-of-ceta-on-generics 2015-03-16T10:45:09+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/84-MD002440.jpg https://gabi-journal-net.server1.ech.be/news/biologicals-dominate-europes-best-sellers 2015-03-18T10:46:31+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/eu-flag-v12k23.jpg https://gabi-journal-net.server1.ech.be/news/ec-expected-to-dish-out-more-pay-for-delay-fines 2015-04-03T10:09:46+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/pay-for-delay-v13c29.jpg https://gabi-journal-net.server1.ech.be/news/switching-and-extrapolation-of-subsequent-entry-biologics-in-canada 2015-04-07T10:11:27+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Efficacy-Extrapolation-Interchangeability-V13D19.jpg https://gabi-journal-net.server1.ech.be/news/use-of-biosimilars-in-europe-differs-across-countries 2015-04-09T10:12:44+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/129-AA010946.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-trastuzumab-similar-to-herceptin-in-non-clinical-study 2015-04-13T10:14:14+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/clinical-trials-v13f14.jpg https://gabi-journal-net.server1.ech.be/news/right-of-appeal-provision-in-ceta 2015-04-17T10:17:10+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/canada-eu-v13j31.jpg https://gabi-journal-net.server1.ech.be/news/trends-in-the-financial-burden-of-diabetes-treatment 2015-04-23T12:04:43+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/diabetes-cure-v14c20.jpg https://gabi-journal-net.server1.ech.be/news/ecco-survey-highlights-lack-of-confidence-in-biosimilar-mabs 2015-04-28T12:06:50+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/IBD-2-V13J25.jpg https://gabi-journal-net.server1.ech.be/news/value-of-generics-overlooked-in-one-country-that-needs-them-most-greece 2015-04-30T12:09:59+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Greece-flag-V13C15.jpg https://gabi-journal-net.server1.ech.be/news/appropriate-generics-pricing-improves-medicines-availability-in-sri-lanka 2015-05-06T12:12:24+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/29-MD002351.jpg https://gabi-journal-net.server1.ech.be/news/adalimumab-biosimilar-has-comparable-pharmacokinetics-to-humira 2015-05-08T12:13:59+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Adalimumab-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/regulating-the-safety-of-biosimilars 2015-05-12T12:16:58+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Quality-similarity-and-safety-V13D12.jpg https://gabi-journal-net.server1.ech.be/news/fda-debuts-purple-book-for-biologicals-and-interchangeable-biosimilars 2015-05-14T12:18:36+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Purple-Book-V14I12.png https://gabi-journal-net.server1.ech.be/news/pharmas-future-in-china-and-the-us 2015-05-18T12:19:48+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/US-China-Flag-V14I12.jpg https://gabi-journal-net.server1.ech.be/news/generic-hepatitis-drug-to-be-made-available-to-80-countries 2015-05-20T12:21:19+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Sovaldi-Sofosbuvir-hep-drug-V14I12.jpg https://gabi-journal-net.server1.ech.be/news/generics-group-calls-for-say-on-ich-standards 2015-05-22T12:22:50+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Generic-V13C05.jpg https://gabi-journal-net.server1.ech.be/news/concerns-from-eu-and-us-over-colombian-biologicals-guidelines 2015-05-26T12:23:51+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Colombia-V14I19.png https://gabi-journal-net.server1.ech.be/news/patient-access-to-rituximab-in-emerging-markets 2015-05-28T12:25:17+00:00 https://gabi-journal-net.server1.ech.be/news/biosimilars-in-emerging-markets 2015-06-01T12:27:01+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Emerging-markets-V14I19.jpg https://gabi-journal-net.server1.ech.be/news/strategy-for-biosimilars-in-china 2015-06-05T12:29:52+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Guidance-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/the-ethics-of-generic-immunosuppressive-drugs 2015-06-03T12:37:20+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Transplant1-AA010155-V13E31.jpg https://gabi-journal-net.server1.ech.be/news/european-initiatives-to-enhance-losartan-utilization-post-generics-impact-and-implications 2015-06-09T12:28:24+00:00 https://gabi-journal-net.server1.ech.be/news/elderly-patients-in-us-lack-knowledge-on-biosimilars 2015-06-19T12:42:05+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/MD002286.jpg https://gabi-journal-net.server1.ech.be/news/thirty-years-of-generics-in-the-us 2015-06-26T12:55:53+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/30-MD001974.jpg https://gabi-journal-net.server1.ech.be/news/generics-and-biosimilars-contribute-to-european-drug-savings 2015-06-25T12:57:16+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Health-on-a-Budget-V13D12.jpg https://gabi-journal-net.server1.ech.be/news/mobilization-of-stem-cells-by-biosimilar-nivestim-and-neupogen 2015-06-29T13:05:39+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Research-V13D05.jpg https://gabi-journal-net.server1.ech.be/news/reference-pricing-and-generics-in-finland 2015-06-26T13:07:25+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Pills-V13D05.jpg https://gabi-journal-net.server1.ech.be/news/extrapolation-for-biosimilars 2015-06-30T13:08:46+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Biosimilars-V13E10.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-bevacizumab-similar-to-avastin-in-preclinical-assessments 2015-07-02T13:10:11+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Bevacizumab-2-V14f01.jpg https://gabi-journal-net.server1.ech.be/news/changes-to-pharmaceutical-policy-during-an-economic-recession 2015-07-06T13:11:33+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/136-AA011035.jpg https://gabi-journal-net.server1.ech.be/news/patients-satisfied-with-generics 2015-07-14T13:18:11+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/118-MD002467.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-similar-but-not-identical 2015-07-20T13:24:21+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/generic-brand-name-v13c01.jpeg https://gabi-journal-net.server1.ech.be/news/predicting-the-response-of-diabetes-patients-to-biosimilar-insulin 2015-07-22T13:25:46+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Diabetes-V14K06.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-when-indications-can-be-extrapolated 2015-07-28T08:48:41+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Checklist-Stethoscope-V14J24.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-use-in-europe-varies-widely 2015-07-30T08:50:39+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/eu-flag-v12k23.jpg https://gabi-journal-net.server1.ech.be/news/extrapolation-of-indications-in-biosimilars-filgrastim 2015-08-03T08:52:11+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Filgrastim-V14K20.jpg https://gabi-journal-net.server1.ech.be/news/use-of-biosimilars-in-rheumatology 2015-08-17T09:04:27+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Rheumatology-RCPI-V13C29.jpg https://gabi-journal-net.server1.ech.be/news/glossary-of-key-terms 2015-05-21T13:52:22+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/76-MD002337.jpg https://gabi-journal-net.server1.ech.be/news/development-of-biosimilars-for-rheumatoid-arthritis 2015-08-23T22:01:45+00:00 https://gabi-journal-net.server1.ech.be/news/use-of-generics-in-cardiovascular-diseases 2017-01-30T11:23:55+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/statin-drug-v15e08.jpg https://gabi-journal-net.server1.ech.be/news/differences-between-biosimilars-and-reference-products 2017-01-30T11:27:28+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/biological-143606710-v14j14ct.jpg https://gabi-journal-net.server1.ech.be/news/fda-includes-follow-on-versions-in-its-new-liposome-guideline 2017-01-30T11:28:40+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/liposome-v15l11.jpg https://gabi-journal-net.server1.ech.be/news/efficacy-and-safety-of-biosimilar-infliximab-compared-to-other-biologicals-in-rheumatoid-arthritis 2017-01-30T11:29:34+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/efficacy-extrapolation-interchangeability-v16e25lb.jpg https://gabi-journal-net.server1.ech.be/news/impact-of-hypertension-generics-in-europe 2017-01-30T11:30:41+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/151-MD002298_medium.jpg https://gabi-journal-net.server1.ech.be/news/extrapolation-of-indications-for-mabs 2017-01-30T11:31:00+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/biological-143606710-v14j14ct.jpg https://gabi-journal-net.server1.ech.be/news/costs-and-prices-of-entecavir-to-treat-hepatitis-b 2017-01-30T11:32:08+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Hepatitis-C-Virus-V14A31.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-a-new-challenge-in-the-current-pharmacology 2017-01-30T11:32:31+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/pharmacology-mit.jpg https://gabi-journal-net.server1.ech.be/news/impact-of-breast-cancer-generics-in-europe 2017-01-30T11:32:48+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/breast-cancer-v15j22.jpg https://gabi-journal-net.server1.ech.be/news/substitution-of-generic-antiepileptic-drugs 2017-01-30T11:41:24+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/label-prescription-drugs.jpg https://gabi-journal-net.server1.ech.be/news/switching-between-originator-and-follow-on-iron-sucrose 2017-03-20T13:14:39+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Real-Fake-V13F14.jpg https://gabi-journal-net.server1.ech.be/news/is-a-new-pathway-for-nbcds-on-the-way-in-the-us 2017-03-20T15:03:56+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/NBCD-2.jpg https://gabi-journal-net.server1.ech.be/news/switching-between-generics-of-anti-epileptic-drugs 2017-03-29T07:16:39+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Epileptic-V16F10.jpg https://gabi-journal-net.server1.ech.be/news/effectiveness-of-esas-in-treating-anaemia-in-kidney-disease-and-cancer-patients 2017-03-31T07:21:05+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Cancer-image015.jpg https://gabi-journal-net.server1.ech.be/news/pharmacists-prefer-generic-otc-medicines 2017-04-03T07:24:31+00:00 https://gabi-journal-net.server1.ech.be/news/immunogenicity-of-biologicals-the-role-of-post-translational-modifications 2017-04-05T07:55:53+00:00 https://gabi-journal-net.server1.ech.be/news/aes-position-statement-on-substitution-of-generic-anti-epileptics 2017-04-12T08:07:44+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Concept-Paper.jpg https://gabi-journal-net.server1.ech.be/news/doctors-want-more-details-in-biosimilars-labelling 2017-04-12T08:10:20+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Labelling-V14I26.jpg https://gabi-journal-net.server1.ech.be/news/ways-to-reduce-drug-costs-in-australia 2017-04-19T08:11:14+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Discount-Save-money-V15c13.jpeg https://gabi-journal-net.server1.ech.be/news/the-satisfaction-of-healthcare-payers-patients-and-physicians-with-generic-imatinib 2017-04-24T08:16:29+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Chronic-myeloid-leukaema-V16H05.jpg https://gabi-journal-net.server1.ech.be/news/ema-adopts-new-guidance-on-monitoring-of-biologicals 2017-04-28T08:45:43+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Health-and-Safety-V15C26.jpg https://gabi-journal-net.server1.ech.be/news/biologicals-characteristics-that-make-them-unique-and-special 2017-08-16T10:53:08+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/01-AA007239.jpg https://gabi-journal-net.server1.ech.be/news/pharmacists-attitudes-towards-domestic-generics-in-afghanistan 2017-08-16T10:56:41+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/09-AA008582.jpg https://gabi-journal-net.server1.ech.be/news/new-pharmaceutical-law-promotes-generics-in-chile 2017-08-16T10:57:28+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/09-AA008582.jpg https://gabi-journal-net.server1.ech.be/news/generic-doxil-approval-may-help-alleviate-drug-shortages 2017-08-16T10:58:24+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/09-AA008582.jpg https://gabi-journal-net.server1.ech.be/news/use-of-formularies-could-increase-use-of-biosimilars 2017-08-16T10:58:58+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/09-AA008582.jpg https://gabi-journal-net.server1.ech.be/news/measures-to-increase-generics-use-in-greece 2017-08-16T11:01:04+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/10-AA008993.jpg https://gabi-journal-net.server1.ech.be/news/generics-perceptions-in-patients-pharmacists-and-doctors 2017-08-16T11:01:58+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/10-AA008993.jpg https://gabi-journal-net.server1.ech.be/news/fda-finally-issues-draft-biosimilar-guidance 2017-08-16T11:02:51+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/10-AA008993.jpg https://gabi-journal-net.server1.ech.be/news/facts-about-generics-for-patients 2017-08-16T11:03:37+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/10-AA008993.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-what-physicians-need-to-know 2017-08-16T11:05:46+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/11-AA010165.jpg https://gabi-journal-net.server1.ech.be/news/european-doctors-have-insufficient-knowledge-of-biosimilars 2017-08-16T11:06:46+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/11-AA010165.jpg https://gabi-journal-net.server1.ech.be/news/positioning-of-biosimilars-commodity-versus-differentiated 2017-08-16T11:07:49+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/11-AA010165.jpg https://gabi-journal-net.server1.ech.be/news/abpi-issues-updated-position-paper-on-biosimilars 2017-08-16T11:08:25+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/11-AA010165.jpg https://gabi-journal-net.server1.ech.be/news/fda-discredits-study-claiming-foreign-generics-tainted 2017-08-16T11:09:51+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/13-AA010182.jpg https://gabi-journal-net.server1.ech.be/news/us67-billion-worth-of-biosimilar-patents-expiring-before-2020 2017-08-16T11:11:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/02-AA010638.jpg https://gabi-journal-net.server1.ech.be/news/improved-labelling-sought-for-biosimilar-acceptance 2017-08-16T11:12:08+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/02-AA010638.jpg https://gabi-journal-net.server1.ech.be/news/pharmacovigilance-for-mabs 2017-08-16T11:12:50+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/02-AA010638.jpg https://gabi-journal-net.server1.ech.be/news/fda-starts-widespread-testing-of-generics 2017-08-16T11:14:18+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/150-AA010692.jpg https://gabi-journal-net.server1.ech.be/news/a-strategic-approach-to-increase-uptake-of-biosimilars-in-spain 2017-08-21T13:32:13+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/22-AA010963.jpg https://gabi-journal-net.server1.ech.be/news/fda-approves-new-suppliers-to-alleviate-cancer-drug-shortages 2017-08-21T13:32:46+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/22-AA010963.jpg https://gabi-journal-net.server1.ech.be/news/ema-opens-up-access-to-reports-on-suspected-drug-side-effects 2017-08-21T13:33:21+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/22-AA010963.jpg https://gabi-journal-net.server1.ech.be/news/ema-responds-to-questions-over-biosimilar-comparability 2017-08-21T13:33:57+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/22-AA010963.jpg https://gabi-journal-net.server1.ech.be/news/barriers-to-biologicals-competition 2017-08-21T13:36:09+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/04-AA010978.jpg https://gabi-journal-net.server1.ech.be/news/european-regulatory-pathways-for-biosimilars 2017-08-21T13:36:49+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/22-AA010963.jpg https://gabi-journal-net.server1.ech.be/news/impact-of-antidepressant-generics-in-europe 2017-08-21T13:37:45+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/04-AA010978.jpg https://gabi-journal-net.server1.ech.be/news/top-developments-in-biosimilars-during-2012 2017-08-21T13:38:35+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/04-AA010978.jpg https://gabi-journal-net.server1.ech.be/news/generic-atypical-antipsychotic-drugs-in-belgium 2017-08-21T13:39:11+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/04-AA010978.jpg https://gabi-journal-net.server1.ech.be/news/development-of-iranian-guidelines-for-biogenerics 2017-08-21T13:41:21+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/23-AA011020.jpg https://gabi-journal-net.server1.ech.be/news/fda-issues-drug-shortage-draft-guidance 2017-08-21T13:42:00+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/23-AA011020.jpg https://gabi-journal-net.server1.ech.be/news/how-the-biosimilars-market-is-changing 2017-08-21T13:44:08+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/05-AA011027.jpg https://gabi-journal-net.server1.ech.be/news/european-uptake-of-biosimilars 2017-08-21T13:44:44+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/05-AA011027.jpg https://gabi-journal-net.server1.ech.be/news/conflict-of-interest-policies-reduce-brand-name-prescribing 2017-08-21T13:45:22+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/05-AA011027.jpg https://gabi-journal-net.server1.ech.be/news/research-on-clinical-trial-issues-for-biosimilars 2017-08-21T13:45:55+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/05-AA011027.jpg https://gabi-journal-net.server1.ech.be/news/challenges-for-the-regulation-of-biosimilars 2017-08-21T13:46:26+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/05-AA011027.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-knowledge-gap-needs-addressing 2017-08-21T13:46:54+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/05-AA011027.jpg https://gabi-journal-net.server1.ech.be/news/extrapolation-of-indications-in-biosimilars-epoetin 2017-08-21T13:47:29+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/05-AA011027.jpg https://gabi-journal-net.server1.ech.be/news/impact-of-measures-to-encourage-generics-prescribing-in-scotland 2017-08-21T13:48:39+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/26-AA011066.jpg https://gabi-journal-net.server1.ech.be/news/indias-patent-laws-coming-under-repeated-challenges 2017-08-21T13:49:52+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/26-AA011066.jpg https://gabi-journal-net.server1.ech.be/news/un-urges-wto-to-keep-cheap-drug-deal-for-poor-countries 2017-08-21T13:50:31+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/26-AA011066.jpg https://gabi-journal-net.server1.ech.be/news/cost-effectiveness-analysis-and-incentivizing-innovation 2017-08-21T13:52:29+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/148-AA011074.jpg https://gabi-journal-net.server1.ech.be/news/generics-reduce-englands-drug-spending 2017-08-21T13:53:07+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/148-AA011074.jpg https://gabi-journal-net.server1.ech.be/news/chinas-sfda-to-fast-track-high-priority-generics 2017-08-21T13:53:40+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/148-AA011074.jpg https://gabi-journal-net.server1.ech.be/news/guiding-principles-for-biosimilars-development 2017-08-21T13:54:10+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/148-AA011074.jpg https://gabi-journal-net.server1.ech.be/news/beyond-biosimilarity 2017-08-21T13:55:32+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/138-AA011155.jpg https://gabi-journal-net.server1.ech.be/news/fda-urged-to-exclude-plasma-protein-therapies-from-biosimilar-pathway 2017-08-21T13:56:35+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/138-AA011155.jpg https://gabi-journal-net.server1.ech.be/news/patients-persuade-doctors-to-prescribe-brand-name-rather-than-generic-drugs 2017-08-21T13:57:06+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/138-AA011155.jpg https://gabi-journal-net.server1.ech.be/news/establishing-mab-biosimilarity-before-reaching-the-clinic 2017-08-21T13:57:53+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/138-AA011155.jpg https://gabi-journal-net.server1.ech.be/news/ema-issues-draft-reflection-paper-for-iron-based-nano-colloidal-products 2017-08-21T13:59:47+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Anaemia-2-V13J18.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-in-the-treatment-of-chemotherapy-induced-anaemia 2017-08-21T14:00:44+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Anaemia-2-V13J18.jpg https://gabi-journal-net.server1.ech.be/news/non-biological-complex-drug-concept-experiences-with-iron-sucrose-and-low-molecular-weight-heparin 2017-08-21T14:01:19+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Anaemia-2-V13J18.jpg https://gabi-journal-net.server1.ech.be/news/pure-red-cell-aplasia-in-a-ckd-patient-after-treatment-with-epoetin-zeta 2017-08-21T14:01:48+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Anaemia-2-V13J18.jpg https://gabi-journal-net.server1.ech.be/news/recall-of-anaemia-drug-highlights-safety-issues-of-nbcds 2017-08-21T14:03:11+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Anaemia-V13D05.jpg https://gabi-journal-net.server1.ech.be/news/epoetin-alfa-biosimilar-effective-in-treating-anaemia 2017-08-21T14:03:44+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Anaemia-V13D05.jpg https://gabi-journal-net.server1.ech.be/news/free-samples-increase-use-of-branded-drugs 2017-08-21T14:05:14+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/ANDA-Approval-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/south-korean-pharma-market-to-reach-us20-billion-by-2020 2017-08-21T14:05:45+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/ANDA-Approval-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/calls-for-biosimilars-to-have-same-inn-at-who-meeting 2017-08-21T14:07:50+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Biologicals-1-NAME-V13J31.jpg https://gabi-journal-net.server1.ech.be/news/eu-majority-says-same-inns-for-biosimilars 2017-08-21T14:08:42+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Biologicals-1-NAME-V13J31.jpg https://gabi-journal-net.server1.ech.be/news/top-8-blockbuster-biologicals-2013 2017-08-21T14:09:23+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Biologicals-1-NAME-V13J31.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-competition-in-europe 2017-08-21T14:11:14+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Biologicals-2-V12K16.jpg https://gabi-journal-net.server1.ech.be/news/sandoz-plans-to-launch-five-more-biosimilars-by-2020 2017-08-21T14:12:02+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Biologicals-2-V12K16.jpg https://gabi-journal-net.server1.ech.be/news/dialogue-needed-to-build-confidence-in-biosimilars 2017-08-21T14:13:26+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Biologicals-2-V12K16.jpg https://gabi-journal-net.server1.ech.be/news/prospects-for-producing-follow-on-biological-products-in-brazil 2017-08-21T14:14:43+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Brazil-flag-V13C03.jpg https://gabi-journal-net.server1.ech.be/news/brazil-speeds-up-approval-process-for-generics-and-biologicals 2017-08-21T14:15:20+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Brazil-flag-V13C03.jpg https://gabi-journal-net.server1.ech.be/news/perceptions-of-the-value-of-generics-in-brazil 2017-08-21T14:15:54+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Brazil-flag-V13C03.jpg https://gabi-journal-net.server1.ech.be/news/results-of-clinical-trials-in-europe-to-be-made-publicly-available 2017-08-23T12:22:11+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/clinical-trials-2-v13k29.jpg https://gabi-journal-net.server1.ech.be/news/phase-iii-study-of-biosimilar-adalimumab-meets-primary-endpoint 2017-08-23T12:22:44+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/clinical-trials-2-v13k29.jpg https://gabi-journal-net.server1.ech.be/news/comparison-of-biosimilar-filgrastim-versus-other-g-csf-formulations-after-autologous-stem-cell-transplantation 2017-08-23T12:23:24+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/clinical-trials-2-v13k29.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-management-of-clinical-issues 2017-08-23T12:23:54+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/clinical-trials-2-v13k29.jpg https://gabi-journal-net.server1.ech.be/news/compliance-and-persistence-same-for-generic-and-brand-name-alendronate 2017-08-23T12:24:56+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/generic-brand-name-v13c01.jpeg https://gabi-journal-net.server1.ech.be/news/brand-name-drugs-also-cut-healthcare-costs 2017-08-23T12:25:27+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/generic-brand-name-v13c01.jpeg https://gabi-journal-net.server1.ech.be/news/generics-losing-out-to-brand-name-drugs-in-croatia 2017-08-23T12:25:52+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/generic-brand-name-v13c01.jpeg https://gabi-journal-net.server1.ech.be/news/payers-in-us-view-biosimilars-as-a-lower-cost-branded-option 2017-08-23T12:26:19+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/generic-brand-name-v13c01.jpeg https://gabi-journal-net.server1.ech.be/news/us-fda-defends-biosimilar-substitution 2017-08-23T12:27:49+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/generic-brand-name-v13c01.jpeg https://gabi-journal-net.server1.ech.be/news/fewer-generics-approved-in-the-us-during-2012 2017-08-23T12:28:36+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Generics-Blue-Cap-V13C15.jpg https://gabi-journal-net.server1.ech.be/news/indias-pharma-moving-from-generics-to-niche-drugs 2017-08-23T12:29:01+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Generics-Blue-Cap-V13C15.jpg https://gabi-journal-net.server1.ech.be/news/reasons-for-the-success-of-a-generics-company-in-the-sudan-market 2017-08-23T12:29:39+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Generics-Blue-Cap-V13C15.jpg https://gabi-journal-net.server1.ech.be/news/international-harmonization-for-biosimilars 2017-08-23T12:31:01+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Harmonize-V13F28.jpg https://gabi-journal-net.server1.ech.be/news/top-10-most-read-gabi-online-articles-in-2013 2017-08-23T12:31:36+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Harmonize-V13F28.jpg https://gabi-journal-net.server1.ech.be/news/iprf-template-for-summary-information-for-biosimilar-reviews 2017-08-23T12:32:21+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Harmonize-V13F28.jpg https://gabi-journal-net.server1.ech.be/news/fdas-labelling-proposal-will-increase-cost-of-generics 2017-08-28T10:44:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Label-FDA-V14b20.png https://gabi-journal-net.server1.ech.be/news/fda-issues-draft-guidance-on-biosimilars-labelling 2017-08-28T10:44:56+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Label-FDA-V14b20.png https://gabi-journal-net.server1.ech.be/news/ranbaxy-faces-lawsuit-in-india 2017-08-28T10:46:28+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Law-V13C29.jpg https://gabi-journal-net.server1.ech.be/news/generics-may-be-allowed-to-change-drug-labelling 2017-08-28T10:47:15+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Law-V13C29.jpg https://gabi-journal-net.server1.ech.be/news/pennsylvania-moves-closer-to-adopting-biosimilars-legislation 2017-08-28T10:47:55+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Law-V13C29.jpg https://gabi-journal-net.server1.ech.be/news/france-to-allow-biosimilars-substitution 2017-08-28T10:48:31+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Law-V13C29.jpg https://gabi-journal-net.server1.ech.be/news/indiana-biosimilars-substitution-bill-becomes-law 2017-08-28T10:49:03+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Law-V13C29.jpg https://gabi-journal-net.server1.ech.be/news/court-rules-canadian-drug-regulators-cannot-control-generics-prices 2017-08-28T10:49:35+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Law-V13C29.jpg https://gabi-journal-net.server1.ech.be/news/development-of-biosimilars-for-rheumatology 2017-08-28T11:45:57+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/X-ray1-MD001877-V13E03.jpg https://gabi-journal-net.server1.ech.be/news/assessment-of-efficacy-and-safety-of-biosimilars-in-rheumatology 2017-08-28T11:46:49+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/X-ray1-MD001877-V13E03.jpg https://gabi-journal-net.server1.ech.be/news/inflammatory-arthritis-auditioning-for-the-role-of-biosimilar 2017-08-28T11:47:18+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/X-ray1-MD001877-V13E03.jpg https://gabi-journal-net.server1.ech.be/news/patients-knowledge-and-perceptions-about-generics-in-australia 2017-08-28T11:48:48+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Patient-MD002316-V13C05.jpg https://gabi-journal-net.server1.ech.be/news/transplant-coordinators-perception-of-generic-immunosuppressants 2017-08-28T11:49:24+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Patient-MD002316-V13C05.jpg https://gabi-journal-net.server1.ech.be/news/biosimilars-what-patients-need-to-know 2017-08-28T11:49:52+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Patient-MD002316-V13C05.jpg https://gabi-journal-net.server1.ech.be/news/proposal-in-brazil-to-exempt-medicines-from-tax 2017-08-28T11:51:23+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/119-MD002332.jpg https://gabi-journal-net.server1.ech.be/news/fda-announces-two-actions-to-combat-drug-shortages 2017-08-28T11:52:53+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/28-MD002360.jpg https://gabi-journal-net.server1.ech.be/news/use-of-generic-cardiovascular-drugs-in-china 2017-08-28T11:53:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/28-MD002360.jpg https://gabi-journal-net.server1.ech.be/news/generics-market-share-in-europe 2017-08-28T11:54:06+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/28-MD002360.jpg https://gabi-journal-net.server1.ech.be/news/amgens-response-to-biosimilar-substitution-legislation-in-us 2017-08-28T11:54:45+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/28-MD002360.jpg https://gabi-journal-net.server1.ech.be/news/generics-in-taiwan-urban-rural-disparity 2017-08-28T11:55:20+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/28-MD002360.jpg https://gabi-journal-net.server1.ech.be/news/robust-data-for-biosimilar-trastuzumab-programmes-presented 2017-08-28T11:57:13+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Stethoscope-MD002364-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/factors-supporting-a-sustainable-european-biosimilars-market 2017-08-28T11:58:03+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Stethoscope-MD002364-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/prescribing-similar-biotherapeutic-products-in-latin-america 2017-08-28T11:58:36+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Stethoscope-MD002364-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/us-doctors-poised-to-prescribe-biosimilars 2017-08-28T11:59:08+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Stethoscope-MD002364-V13F21.jpg https://gabi-journal-net.server1.ech.be/news/the-non-financial-benefits-of-generics-substitution 2017-08-28T12:00:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/109-MD002387.jpg https://gabi-journal-net.server1.ech.be/news/impact-of-south-koreas-new-drug-pricing-policy-on-market-competition 2017-08-28T12:01:22+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/109-MD002387.jpg https://gabi-journal-net.server1.ech.be/news/overview-of-research-on-regulatory-issues-surrounding-biosimilars-in-2012 2017-08-28T12:02:06+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/109-MD002387.jpg https://gabi-journal-net.server1.ech.be/news/canadas-generics-are-too-expensive 2017-08-28T12:05:15+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/109-MD002387.jpg https://gabi-journal-net.server1.ech.be/news/momenta-versus-amphastar-and-the-safe-harbour-provision 2017-08-28T12:07:37+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/79-MD002389.jpg https://gabi-journal-net.server1.ech.be/news/overview-of-clinical-research-on-generics-in-2012 2017-08-28T12:08:10+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/79-MD002389.jpg https://gabi-journal-net.server1.ech.be/news/generics-save-us-1-2-trillion-over-last-10-years 2017-08-28T12:09:15+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/79-MD002389.jpg https://gabi-journal-net.server1.ech.be/news/impact-of-price-cuts-on-spending-on-hyperlipidaemic-drugs-in-south-korea 2017-08-28T12:09:46+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/79-MD002389.jpg https://gabi-journal-net.server1.ech.be/news/generics-save-us-1-5-trillion-over-last-10-years 2017-08-28T12:10:11+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/79-MD002389.jpg https://gabi-journal-net.server1.ech.be/news/use-of-brand-name-drugs-increasing-healthcare-costs-in-us 2017-08-28T12:12:36+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Clinician2-MD002395-V13H02.jpg https://gabi-journal-net.server1.ech.be/news/physicians-believe-biosimilars-should-have-different-names 2017-08-28T12:13:11+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Clinician2-MD002395-V13H02.jpg https://gabi-journal-net.server1.ech.be/news/irish-pharmacists-perceptions-and-attitudes-towards-generics 2017-08-28T12:13:44+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Clinician2-MD002395-V13H02.jpg https://gabi-journal-net.server1.ech.be/news/physicians-and-pharmacists-perspectives-on-generics-use 2017-08-28T12:14:14+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Clinician2-MD002395-V13H02.jpg https://gabi-journal-net.server1.ech.be/news/generics-reduce-costs-and-increase-access 2017-08-28T12:15:54+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/60-MD002436.jpg https://gabi-journal-net.server1.ech.be/news/fda-gives-generics-greater-importance 2017-08-28T12:16:35+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/60-MD002436.jpg https://gabi-journal-net.server1.ech.be/news/perceptions-of-the-effectiveness-and-quality-of-generics 2017-08-28T12:17:49+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/27-MD002442.jpg https://gabi-journal-net.server1.ech.be/news/fda-discusses-biosimilars-guidance 2017-08-28T12:18:24+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/27-MD002442.jpg https://gabi-journal-net.server1.ech.be/news/promoting-generics-prescribing-in-the-uk 2017-08-28T12:45:20+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/27-MD002442.jpg https://gabi-journal-net.server1.ech.be/news/american-made-prescription-drugs-76-cheaper-when-purchased-abroad 2017-08-30T12:22:22+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/112-MD002452.jpg https://gabi-journal-net.server1.ech.be/news/paediatric-use-of-low-cost-generic-programs-in-the-us 2017-08-30T12:23:06+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/112-MD002452.jpg https://gabi-journal-net.server1.ech.be/news/perception-and-knowledge-of-generics-in-portugal 2017-08-30T12:23:42+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/112-MD002452.jpg https://gabi-journal-net.server1.ech.be/news/cesp-makes-submissions-totally-electronic 2017-08-30T12:24:27+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/112-MD002452.jpg https://gabi-journal-net.server1.ech.be/news/ccm-and-biocon-make-biosimilar-insulin-deal 2017-08-30T12:26:00+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/122-MD002454.jpg https://gabi-journal-net.server1.ech.be/news/impact-of-coupons-on-adherence-to-statins 2017-08-30T12:26:36+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/122-MD002454.jpg https://gabi-journal-net.server1.ech.be/news/attitudes-towards-generics-in-turkey 2017-08-30T12:27:07+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/122-MD002454.jpg https://gabi-journal-net.server1.ech.be/news/consumer-choice-between-generic-and-brand-name-medicines-in-a-small-generics-market 2017-08-30T12:28:23+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/87-MD002465.jpg https://gabi-journal-net.server1.ech.be/news/driving-down-drug-prices-how-regulators-can-influence-affordability 2017-08-30T12:29:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/88-MD002468.jpg https://gabi-journal-net.server1.ech.be/news/abbott-asks-fda-to-block-adalimumab-biosimilar 2017-08-30T12:30:17+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/88-MD002468.jpg https://gabi-journal-net.server1.ech.be/news/confusion-exists-in-brazil-over-generics 2017-08-30T12:31:54+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/88-MD002468.jpg https://gabi-journal-net.server1.ech.be/news/physicians-views-on-generics-in-the-philippines 2017-08-30T12:32:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/88-MD002468.jpg https://gabi-journal-net.server1.ech.be/news/are-biosimilars-worth-it 2017-08-30T12:34:33+00:00 https://gabi-journal-net.server1.ech.be/news/impact-of-generics-on-european-budgets 2017-08-30T12:35:54+00:00 https://gabi-journal-net.server1.ech.be/news/uk-launches-generic-medicines-forum 2017-08-30T12:37:24+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/meeting-v13f14.jpg https://gabi-journal-net.server1.ech.be/news/global-and-national-biosimilars-players-increasing 2017-08-30T12:38:03+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/meeting-v13f14.jpg https://gabi-journal-net.server1.ech.be/news/a-multidisciplinary-perspective-on-biosimilars 2017-08-30T12:38:43+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/meeting-v13f14.jpg https://gabi-journal-net.server1.ech.be/news/fight-continues-over-biosimilar-naming-standards 2017-08-30T12:40:00+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Naming-1-V13I27.jpg https://gabi-journal-net.server1.ech.be/news/who-naming-of-biosimilars 2017-08-30T12:40:22+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Naming-1-V13I27.jpg https://gabi-journal-net.server1.ech.be/news/jj-adds-its-opinion-to-biosimilars-naming-debate 2017-08-30T12:41:02+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Naming-1-V13I27.jpg https://gabi-journal-net.server1.ech.be/news/gpha-proposes-using-manufacturer-names-to-distinguish-biosimilars 2017-08-30T12:41:39+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Naming-1-V13I27.jpg https://gabi-journal-net.server1.ech.be/news/survey-highlights-the-importance-of-unique-names-for-biosimilars 2017-08-30T12:44:18+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Naming-3-V13J04.jpg https://gabi-journal-net.server1.ech.be/news/who-proposal-offers-clarity-for-biosimilar-nomenclature 2017-08-30T12:46:05+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Naming-3-V13J04.jpg https://gabi-journal-net.server1.ech.be/news/the-cost-of-evergreening-strategies 2017-08-30T12:47:10+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Patent-2-V13E31.png https://gabi-journal-net.server1.ech.be/news/eu-problematic-patent-settlements-remain-at-low-level 2017-08-30T12:47:41+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Patent-2-V13E31.png https://gabi-journal-net.server1.ech.be/news/uk-court-invalidates-herceptin-patents 2017-08-30T12:48:11+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Patent-2-V13E31.png https://gabi-journal-net.server1.ech.be/news/washington-state-legislation-on-biosimilars 2017-08-30T12:53:47+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Regulation-V13H16.jpg https://gabi-journal-net.server1.ech.be/news/regulatory-principles-for-biosimilar-monoclonal-antibodies 2017-08-30T12:54:18+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Regulation-V13H16.jpg https://gabi-journal-net.server1.ech.be/news/europe-japan-cooperation-on-generics-and-biosimilars-regulation 2017-08-30T12:54:52+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Regulation-V13H16.jpg https://gabi-journal-net.server1.ech.be/news/who-calls-for-better-science-based-regulations-for-biosimilars 2017-08-30T12:55:19+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Regulation-V13H16.jpg https://gabi-journal-net.server1.ech.be/news/clinical-and-regulatory-issues-for-biosimilars 2017-08-30T12:55:51+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Regulation-V13H16.jpg https://gabi-journal-net.server1.ech.be/news/remsima-approved-in-colombia 2017-08-30T12:56:59+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Remsima-V14A10.png https://gabi-journal-net.server1.ech.be/news/bsg-guidance-recommends-switching-to-biosimilar-infliximab 2017-08-30T12:57:38+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Remsima-V14A10.png https://gabi-journal-net.server1.ech.be/news/cost-savings-from-use-of-biosimilars-in-rheumatology 2017-08-30T12:59:07+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Rheumatology.org-V13H09.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-rituximab-in-biological-naive-rheumatoid-arthritis-patients 2017-08-30T12:59:37+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Rheumatology.org-V13H09.jpg https://gabi-journal-net.server1.ech.be/news/possibility-of-substitution-of-biosimilars-in-europe 2017-08-30T13:01:08+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Substitution-V13F14.jpg https://gabi-journal-net.server1.ech.be/news/therapeutic-substitution-could-save-americans-money 2017-08-30T13:01:40+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Substitution-V13F14.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-epoetin-%ce%ba-equivalent-to-epoetin-%ce%b2 2017-08-30T13:02:08+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Substitution-V13F14.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-infliximab-comparable-to-remicade 2017-08-30T13:02:35+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Substitution-V13F14.jpg https://gabi-journal-net.server1.ech.be/news/study-results-show-safety-of-switching-to-biosimilar-infliximab 2017-08-30T13:03:04+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Substitution-V13F14.jpg https://gabi-journal-net.server1.ech.be/news/monoclonal-antibodies-and-the-challenge-of-substitution 2017-08-30T13:03:41+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Substitution-V13F14.jpg https://gabi-journal-net.server1.ech.be/news/switching-between-different-esas 2017-08-30T13:04:04+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Substitution-V13F14.jpg https://gabi-journal-net.server1.ech.be/news/biosimilar-g-csf-safe-for-mobilization-of-stem-cells 2017-08-30T13:05:15+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Trust.jpg https://gabi-journal-net.server1.ech.be/news/us-biosimilar-uptake-in-the-light-of-obamacare 2017-08-30T13:05:42+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Trust.jpg https://gabi-journal-net.server1.ech.be/news/japan-proving-to-be-a-favourable-market-for-biosimilars 2017-08-30T13:06:12+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Trust.jpg https://gabi-journal-net.server1.ech.be/news/oecd-report-finds-reduction-in-spending-on-health 2025-07-24T10:39:48+00:00